Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease
Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease
复制标题
DOI：
10.3389/fneur.2019.01388
复制
发表时间：
2020-01-21
影响因子：
3.4
通讯作者：
Wu, Yih-Ru
中科院分区：
文献类型：
--
作者：
Chang, Chun-Wei;Yang, Shieh-Yueh;Wu, Yih-Ru
背景：帕金森病（PD）是第二常见的神经退行性疾病，α -突触核蛋白在PD的发病机制中起关键作用。关于运动严重程度与PD患者外周血α -突触核蛋白水平之间的相关性，研究显示了有争议的结果。目的：检测PD患者血浆和血清α -突触核蛋白水平，探讨血浆和血清α -突触核蛋白水平与运动症状严重程度的关系。方法：我们招募了88名参与者（48名PD患者和40名健康对照）。收集临床资料，抽取每位参与者的静脉血进行血浆或血清处理。采用磁性纳米颗粒单克隆抗体检测血浆或血清α -突触核蛋白水平，并通过免疫磁还原法测定。定量检测血浆或血清α -突触核蛋白水平。结果：PD患者血浆α -突触核蛋白均值为3.60 +/- 2.53，血清α -突触核蛋白均值为0.03 +/- 0.04 pg/mL。血浆和血清α -突触核蛋白受体工作特征曲线下面积分别为0.992和0.917。血清α -synuclein水平与H-Y 1-3期患者也有显著相关性（r = 0.40, p = 0.025），提示血清α -synuclein水平可能是早期PD患者运动症状严重程度的潜在标志。结论：我们的数据表明，血清或血浆α -突触核蛋白水平可以区分健康人与PD患者。血清α -突触核蛋白水平与早期PD患者的运动严重程度中度相关。
Background: Parkinson's disease (PD) is the second most common neurodegenerative disease, and alpha-synuclein plays a critical role in the pathogenesis of PD. Studies have revealed controversial results regarding the correlation between motor severity and alpha-synuclein levels in peripheral blood from patients with PD.Objective: We examined alpha-synuclein levels in plasma or serum in patients with PD and investigated the relationship between plasma or serum alpha-synuclein level and motor symptom severity.Methods: We recruited 88 participants (48 patients with PD and 40 healthy controls). Clinical information was collected, and venous blood was drawn from each participant to be processed to obtain plasma or serum. The plasma or serum alpha-synuclein level was detected using monoclonal antibodies with magnetic nanoparticles, and was measured through immunomagnetic reduction. Plasma or serum alpha-synuclein levels were quantitatively detected.Results: In patients with PD, the means of plasma and serum alpha-synuclein level were 3.60 +/- 2.53 and 0.03 +/- 0.04 pg/mL, respectively. The areas under the receiver operating characteristic curve of plasma and serum alpha-synuclein for distinguishing patients with PD from healthy controls were 0.992 and 0.917, respectively. The serum alpha-synuclein level also showed a significant correlation with patients in H-Y stages 1-3 (r = 0.40, p = 0.025), implying that the serum alpha-synuclein level may be a potential marker of motor symptom severity in patients with early PD.Conclusions: Our data suggest that the alpha-synuclein level in serum or plasma can differentiate between healthy controls and patients with PD. Serum alpha-synuclein levels moderately correlate with motor severity in patients with early PD.